Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17589999 | 0.80 | SMN1; SMN2 (0.42) | MAPTL3MBTL1PDE10ASMN1; SMN2KMT2A | |
| SCHEMBL30020920 | 0.80 | MET (0.47) | MAPTL3MBTL1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL6900306 | 0.80 | MET (0.47) | MAPTL3MBTL1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL21883518 | 0.79 | MET (0.46) | MAPTL3MBTL1KMT2AALDH1A1MET | |
| SCHEMBL30021455 | 0.79 | MET (0.46) | MAPTL3MBTL1KMT2AALDH1A1MET | |
| SCHEMBL21740864 | 0.77 | MTOR (0.41) | L3MBTL1SMN1; SMN2KMT2AALDH1A1NPSR1 | |
| SCHEMBL6899000 | 0.76 | PDE10A (0.44) | MAPTL3MBTL1PDE10ASMN1; SMN2KMT2A | |
| SCHEMBL31339147 | 0.75 | MTOR (0.48) | MAPTL3MBTL1SMN1; SMN2KMT2ANPSR1 | |
| SCHEMBL1609125 | 0.75 | MTOR (0.48) | MAPTL3MBTL1SMN1; SMN2KMT2ANPSR1 | |
| SCHEMBL23122412 | 0.74 | SMN1; SMN2 (0.48) | MAPTL3MBTL1PDE10ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828990-B2 | N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086840-A1 | N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX7, P2RY1, PNP | MAPT 4237/4885L3MBTL1 3516/4885PDE10A 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.